Table 1

Baseline demographics and disease characteristics for the three proof-of-concept trials. BMI, body mass index; CV, coefficient of variation; ND, not determined; VAS, visual analog scale; PGA, patient global assessment; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; IGA, investigator global assessment; PASI, psoriasis area-and-severity index; SD, standard deviation.

PsoriasisRheumatoid arthritisUveitis
AIN457 (3 mg/kg)PlaceboAIN457 (10 mg/kg)PlaceboAIN457 (10 mg/kg)
n = 18n = 18n = 26n = 26n = 16
Age (years) (mean ± SD)50.7 ± 8.7350.9 ± 12.0449.9 ± 8.5349.8 ± 15.1942.6 ± 14.88
Male, n (%)11 (61)13 (72)7 (27)6 (23)4 (25)
Caucasians, n (%)17 (94)17 (94)23 (88)22 (85)7 (44)
BMI (kg/m2) (mean ± SD)32.97 ± 7.4433.79 ± 10.5428.48 ± 6.6628.13 ± 5.58ND
PASI (mean ± SD)18.5 ± 8.718.3 ± 8.1
IGA score, n (%)
  2 (mild)0 (0)1
  3 (moderate)13 (72)11 (61)
  4 (severe)5 (28)5 (28)
  5 (very severe)0 (0)1 (6)
Rheumatoid factor positive (≥10), n (%)1416 (62)
Disease duration (years), median (range)3.9 (1–20)2.9 (1–37)
DAS28 (mean ± SD)6.48 ± 5.737.44 ± 8.85
CRP (mg/L), geometric mean (CV%)6.25 (113.2)10.11 (150.0)
Previous DMARD, n (%)
  123 (88%)24 (92%)
  23 (12%)2
PGA on 100-mm VAS (mean ± SD)67.3 ± 15.8462.1 ± 19.09
IGA on 100-mm VAS (mean ± SD)62.3 ± 17.8565.0 ± 19.20